A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2016
Price : $35 *
At a glance
- Drugs P 1037 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms CLEAN-CF
- Sponsors Vertex Pharmaceuticals
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 27 Apr 2016 Results published in Vertex media release.
- 12 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.